tirzepatide semaglutide head to head produced more average weight loss than in direct head-to-head research., But more weight loss does not automatically mean a medication is better for you., Semaglutide primarily First head-to-head study in people

How to determine your eligibility for GLP-1 medications through personalized assessments

Network meta-analyses suggest that higher-dose semaglutide (1 mg and 2 mg weekly) and tirzepatide (a dual GIP/GLP-1 receptor agonist) demonstrate superior A1c reductions compared to other agents in the class, with mean reductions of 1.52.0% or greater from baseline

At 5 mg/mL concentration, that same 1.0 mg dose becomes 20 units

This affordability model eliminates the primary barrier preventing millions from accessing semaglutide for weight management

However, the unit measurements you draw for each of these doses depend entirely on your concentration

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis